Keyhani-Rofagha S, O'Toole R V, Farrar W B, Sickle-Santanello B, DeCenzo J, Young D
Department of Pathology, Ohio State University College of Medicine, Columbus.
Cancer. 1990 Apr 1;65(7):1577-82. doi: 10.1002/1097-0142(19900401)65:7<1577::aid-cncr2820650721>3.0.co;2-d.
To evaluate DNA content as an independent, long-term prognostic indicator in infiltrative, node-negative adenocarcinoma of the breast, flow cytometric DNA analyses were performed retrospectively in 165 patients. The exclusive use of paraffin-embedded tissue permitted the study of patients for whom 3 to 15 years' follow-up was available. Other investigators have shown a relationship between DNA nuclear content and well-known prognostic indicators of breast carcinoma, such as estrogen receptors, age, menopausal status, and stage of tumor. However, very few of these studies were based on patients with long-term clinical follow-up and investigated the independent prognostic value of DNA nuclear content. The frequency of aneuploidy in the patients in this study was 57%, with DNA indices ranging from 0.73 to 2.59. Survival in patients with localized breast carcinoma with DNA aneuploid tumors was 84.1% at 5 years and 75.5% at 10 years. Those with diploid tumors showed survival of 87.8% at 5 years and 73.4% at 10 years. These data show no independent prognostic value for DNA nuclear content. The relationship between DNA content, tumor histologic type, and age was also investigated. High-grade tumors were more often aneuploid. There was no association between DNA content and age. Of 165 patients, information regarding estrogen receptor status was available in only 77; 45% of those with aneuploid tumors and 35% with diploid tumors were estrogen receptor-negative. This difference was not significant. The authors conclude that simple determination of DNA ploidy fails to indicate prognosis for infiltrative, node-negative breast carcinoma.
为评估DNA含量作为浸润性、淋巴结阴性乳腺癌的一项独立长期预后指标的价值,我们对165例患者进行了回顾性流式细胞术DNA分析。仅使用石蜡包埋组织使得我们能够对那些有3至15年随访资料的患者进行研究。其他研究者已表明DNA核含量与乳腺癌一些众所周知的预后指标之间存在关联,如雌激素受体、年龄、绝经状态及肿瘤分期。然而,这些研究中很少有基于长期临床随访患者的,也未探究DNA核含量的独立预后价值。本研究患者中异倍体的发生率为57%,DNA指数范围为0.73至2.59。DNA异倍体肿瘤的局限性乳腺癌患者5年生存率为84.1%,10年生存率为75.5%。二倍体肿瘤患者5年生存率为87.8%,10年生存率为73.4%。这些数据表明DNA核含量无独立预后价值。我们还研究了DNA含量、肿瘤组织学类型与年龄之间的关系。高级别肿瘤更常为异倍体。DNA含量与年龄之间无关联。165例患者中,仅77例有雌激素受体状态信息;异倍体肿瘤患者中45%雌激素受体阴性,二倍体肿瘤患者中35%雌激素受体阴性。这种差异无统计学意义。作者得出结论,单纯测定DNA倍体无法提示浸润性、淋巴结阴性乳腺癌的预后。